Spectral Medical Announces Amendment And Extension Of Exclusive Supply And Distribution Agreement With Baxter Healthcare Corporation
Portfolio Pulse from Benzinga Newsdesk
Spectral Medical Inc. has extended its exclusive supply and distribution agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (BAX), for the distribution of PMX products in the U.S. and Canada. The extension is for ten years following U.S. FDA marketing authorization for PMX, a device for treating septic shock. Baxter has exercised its option to maintain exclusive distribution rights after Spectral reached a milestone of enrolling 90 patients in its Tigris Trial for PMX.
February 21, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baxter International Inc. extends its exclusive distribution agreement with Spectral Medical for PMX products in the U.S. and Canada, reinforcing its commitment to advanced blood filtration therapies.
The extension of the exclusive distribution agreement for PMX products strengthens Baxter's position in the advanced blood filtration market and demonstrates its commitment to bringing innovative therapies to critically ill patients. This strategic move is likely to have a positive impact on Baxter's stock in the short term, as it underscores the company's ongoing efforts to expand its product portfolio and solidify its market presence in critical care solutions.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80